Syneos Health Opens New Hyderabad Facility, Strengthening Its AI and Life Sciences GCC Strategy

Hyderabad is strengthening its position as a strategic destination for global life sciences and healthcare technology operations, with Syneos Health opening a new facility at Phoenix Equinox in Gachibowli.

The new centre is significant not only because of its scale, but also because of its mandate. Syneos Health is positioning the Hyderabad facility as a strategic hub for artificial intelligence, data and technology, bringing together scientific expertise, biopharmaceutical knowledge and engineering capabilities to support the development, safety and commercialisation of therapies.

Hyderabad Facility Becomes a Major Global Hub

The new Hyderabad centre is described as Syneos Health’s largest facility in Asia and its third-largest globally. The expansion reinforces the company’s growing presence in a city that has developed a strong ecosystem spanning pharmaceuticals, biotechnology, clinical research, healthcare technology and advanced analytics.

Headquartered in Morrisville, North Carolina, Syneos Health has a global workforce of more than 26,000 people and provides services across the biopharmaceutical lifecycle, including clinical development, medical affairs and commercialisation.

The company’s existing Hyderabad presence has been based at Raheja Mindspace in HITEC City. The new Gachibowli facility adds another strategic dimension to its operations in India.

From Traditional GCC to AI-Powered Healthcare Innovation

The most important aspect of the expansion is the role being assigned to the Hyderabad hub.

Rather than operating primarily as a conventional shared-services centre, Syneos Health is building the location around AI, data and technology excellence. The objective is to combine technology capabilities with domain expertise in clinical development, patient safety and commercialisation.

This reflects a broader transformation taking place across India’s GCC ecosystem. Global organisations are increasingly establishing specialised teams in areas such as:

• Generative AI
• Data engineering
• Advanced analytics
• Machine learning
• Clinical technology
• AI product development
• Responsible AI and compliance
• Digital transformation

The shift signals a move away from the traditional cost-arbitrage model toward high-value, knowledge-intensive GCC operations.

AI at the Centre of the Hyderabad Strategy

Syneos Health’s Hyderabad AI Hub is designed to support the application of AI across clinical development, safety and commercialisation.

The company describes the hub as a place where AI capabilities work alongside clinicians, safety scientists and commercial specialists. Its stated focus includes building technology that can address real-world healthcare and biopharmaceutical challenges rather than treating AI as an isolated experimentation function.

The organisation is also building capabilities across the AI and data lifecycle, including GenAI engineering, prompt specialisation, MLOps, data engineering, data science, AI product management, responsible AI, quality engineering and enterprise architecture.

This combination of domain expertise + technology + AI could become one of the defining characteristics of the new Hyderabad operation.

Creating a New Talent Model for Life Sciences

The expansion also highlights the changing talent requirements within healthcare-focused GCCs.

Syneos Health’s current Hyderabad hiring pipeline includes roles across safety and pharmacovigilance, data, technology, quality, cybersecurity, clinical programming and transformation. Its careers portal currently lists multiple Hyderabad opportunities, including Safety & PV Specialists, Validation & QA Analysts, QA Testers, Senior Transformation Analysts and Cyber Resiliency professionals.

The company’s broader Hyderabad AI strategy is expected to require professionals who can operate at the intersection of technology and life sciences.

This creates demand for a new category of talent: professionals who understand not only AI and data engineering, but also the regulatory, scientific and operational requirements of healthcare.

Why This Matters for Hyderabad’s GCC Ecosystem

Syneos Health’s investment adds another important dimension to Hyderabad’s GCC story.

The city has traditionally been recognised for its IT and pharmaceutical strengths. Increasingly, however, these two ecosystems are converging.

Healthcare companies can now tap into:

Pharmaceutical expertise + clinical research + engineering talent + AI capabilities + advanced analytics

That combination makes Hyderabad increasingly attractive for global organisations looking to build specialised healthcare technology and innovation centres.

Syneos Health’s new facility is therefore more than an office expansion. It represents the emergence of life sciences GCCs as technology and innovation engines.

The Bigger GCC Trend

The Syneos Health expansion reflects a broader change in how multinational companies are approaching their India operations.

Earlier generations of GCCs were often established around finance, IT support, customer operations and other shared services. Today’s centres are increasingly being designed around product engineering, AI, analytics, R&D, digital transformation and strategic decision support.

The healthcare sector is particularly suited to this evolution because AI and advanced analytics can be applied across complex workflows—from clinical development and safety monitoring to commercial strategy.

For companies such as Syneos Health, India offers access to both the technology talent required to build these capabilities and the scientific expertise needed to apply them responsibly.

A Strategic Milestone for Syneos Health and Hyderabad

The opening of Syneos Health’s new Hyderabad facility comes at a time when the company is accelerating its AI strategy globally. Syneos Health recently highlighted efforts to advance AI-powered clinical capabilities and improve decision-making across its biopharmaceutical services.

Against this backdrop, Hyderabad’s role becomes increasingly strategic.

The new centre demonstrates how a GCC can evolve from a delivery location into a global capability and innovation hub, with responsibility for technology, data, AI and domain-specific transformation.

For Hyderabad, it strengthens the city’s position as one of India’s leading destinations for life sciences-driven GCC growth.

For Syneos Health, it provides a platform to bring together AI, engineering and biopharmaceutical expertise to accelerate the journey from scientific discovery to patient impact.

GCC Lens Take

Syneos Health’s Hyderabad expansion is a strong example of the next generation of GCCs—where the objective is no longer simply to deliver services from India, but to build specialised capabilities that directly influence global business outcomes.

The combination of AI, data, engineering and life sciences expertise could make the Hyderabad hub an important part of Syneos Health’s global innovation strategy.

As more healthcare and pharmaceutical companies follow a similar path, Hyderabad’s GCC ecosystem could increasingly evolve into a global centre for AI-powered healthcare innovation.